Fund shareholders of AnaptysBio Inc
ISIN US0327241065 · United States · LEI 529900HH4WQT03IG1A12
- Fund shareholders
- 204
- Of which ETFs
- 49 155 other funds
- Value held
- 327.8M $
- Share of capital
- 19.1 % of 29.1M shares on Apr 23, 2026
- Sold short
- 0.6 % by 1 fund, as of Aug 20, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| ProShares Hedge Replication ETF ProShares Trust | 19 | 1K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Avantis Responsible U.S. Equity ETF American Century ETF Trust | 18 | 990.9 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 6 | 330.3 $ | 0.03 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 5 | 277.3 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| CapForce IBD 50 ETF Capital Force ETF Trust | 4.18 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 1.78 % | as of Apr 30, 2026 ↗ |
| Victory RS Science & Technology Fund Victory Portfolios | 1.41 % | as of Mar 31, 2026 ↗ |
| Tactical Growth Allocation Fund Tactical Investment Series Trust | 1.34 % | as of Mar 31, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 1.08 % | as of Apr 30, 2026 ↗ |
| Golden Eagle Dynamic Hypergrowth ETF ETF Opportunities Trust | 1.07 % | as of Mar 31, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 0.99 % | as of Feb 28, 2026 ↗ |
| Victory Science & Technology Fund Victory Portfolios III | 0.88 % | as of Apr 30, 2026 ↗ |
| First Trust Small Cap Growth AlphaDEX Fund First Trust Exchange-Traded AlphaDEX Fund | 0.87 % | as of Apr 30, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 0.78 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 204 | +55 | 5,558,090 | +9.5 % |
| 2026Q1 | 149 | -5 | 5,078,151 | -1.9 % |
| 2025Q4 | 154 | +6 | 5,178,016 | -10.9 % |
| 2025Q3 | 148 | -3 | 5,811,558 | -8.5 % |
| 2025Q2 | 151 | -9 | 6,350,201 | -29.2 % |
| 2025Q1 | 160 | -7 | 8,974,303 | +1.1 % |
| 2024Q4 | 167 | +4 | 8,880,018 | +16.7 % |
| 2024Q3 | 163 | +7 | 7,608,779 | +36.6 % |
| 2024Q2 | 156 | +2 | 5,568,729 | +17.9 % |
| 2024Q1 | 154 | -14 | 4,725,155 | -19.7 % |
| 2023Q4 | 168 | 5,881,891 |
Short sellers of AnaptysBio Inc
Regulators publish the open short positions in this company. Titelia read them from quivad on Aug 20, 2026: today's figure
| Seller | Position | Disclosed on |
|---|---|---|
| PDT Partners, LLC | 0.6 % | Feb 7, 2018 |
Institutional managers
198 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| EcoR1 Capital, LLC | 7,880,094 | 437M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 1,681,380 | 93.2M $ | as of Mar 31, 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1,330,879 | 73.8M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 993,905 | 55.1M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 992,445 | 55M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 940,000 | 52.1M $ | as of Mar 31, 2026 |
| Sanofi | 821,917 | 30.4M $ | as of Mar 31, 2026 |
| Palo Alto Investors LP | 638,161 | 35.4M $ | as of Mar 31, 2026 |
| 683 Capital Management, LLC | 625,000 | 34.7M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 579,296 | 32.1M $ | as of Mar 31, 2026 |
| First Light Asset Management, LLC | 565,431 | 31.4M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 520,241 | 28.9M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 501,086 | 27.8M $ | as of Mar 31, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 492,120 | 27.3M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 475,572 | 26.4M $ | as of Mar 31, 2026 |
| FMR LLC | 472,704 | 26.2M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 465,083 | 25.8M $ | as of Mar 31, 2026 |
| FEDERATED HERMES, INC. | 364,121 | 20.2M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 344,256 | 19.1M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 332,743 | 18.5M $ | as of Mar 31, 2026 |
| Synergy Asset Management, LLC | 317,106 | 17.6M $ | as of Mar 31, 2026 |
| Nuveen, LLC | 316,065 | 17.5M $ | as of Mar 31, 2026 |
| Squarepoint Ops LLC | 267,703 | 14.8M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 254,736 | 14.1M $ | as of Mar 31, 2026 |
| Sofinnova Investments, Inc. | 248,253 | 13.8M $ | as of Mar 31, 2026 |
Declared shareholders of AnaptysBio Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Sirenia Capital Management LP and 1 other | 6.70 % | 1,920,402 | as of Mar 31, 2026 · SCHEDULE 13G |
| Point72 Asset Management, L.P. and 2 others | 0.20 % | 55,303 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of AnaptysBio Inc". https://titelia.com/en/stocks/anaptysbio-inc-US0327241065